Amicus Therapeutics (FOLD) 10-K2016 FY Annual report

Filed: 1 Mar 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abide, ACA, actionin, aimed, alanine, alpha, ALT, ambulatory, aminotransferase, Annex, arisen, ASC, aspartate, AST, background, bactericidal, batch, biosimiliar, Bologna, built, buyback, cancer, cap, capped, Carolina, chain, CK, Cohort, compensatory, complaint, comprised, concomitant, consecutive, constitute, conversion, coordinate, corruptly, creatine, deal, debate, Dermatology, di, dismissed, DOJ, dollar, EC, elevated, encoding, essential, exceeding, FCPA, FD, FIFO, fifteen, filer, fundamental, GCM, GD, GDPR, GI, Grosvenor, HCI, Hexose, HHS, immaterial, incremental, indenture, indirect, infancy, Inspector, installment, interlocutor, interstate, irrespective, Joinder, Justice, kinase, MA, MAH, margin, Master, mentioned, MiaMed, migalastatHCI, mismanagement, modification, morbidity, motion, Naive, neurodegenerative, North, older, passed, PD, persistent, PMDA, predominance, prejudice, prepay, privileged, proportionate, Pub, PUMA, purpose, qualitative, quantitative, rapporteur, rarity, recertified, refiled, relay, repurchase, repurchased, SAP, sectionDecember, semiannually, sensory, shipment, shipping, SmPC, Standing, Step, strike, subscribe, territory, Tetrasaccharide, theGDPR, thing, title, translated, translation, Trust, trustee, unamortized, unchanged, unexpired, Universit, unwinding, usable, verify, visual, walk, Wilmington

Removed: analyzed, annum, Barer, Biomarin, Black, CA, California, capillary, categorization, central, chronically, circulation, classify, closed, commissioned, descriptive, Diego, drew, eGFR, enhanced, enrolled, exit, filtration, forma, GFR, glomerular, glucocerobrosidase, Integrated, interstitial, iohexol, IPO, left, lender, lending, mg, MidCap, military, Navy, Nephrology, Oxford, persuade, pro, protracted, rationalize, redeemable, rendered, repayment, responder, San, short, Silicon, Sol, streamline, subgroup, subsidiary, successive, SVB, switched, syndicate, tool, tranche, unaudited, unblinding, undergo, unique, vacated, Valley, variability, ventricular

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

FOLD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

QuickLinks -- Click here to rapidly navigate through this document

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

1.: Registration Statement (Form S-3ASR No. 333-212414) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers
2.: Registration Statement (Form S-3ASR No. 333-211005) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers
3.: Registration Statement (Form S-3ASR No. 333-207210) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers
4.: Registration Statement (Form S-8 No. 333-197202) pertaining to the Amicus Therapeutics, Inc. Cash Deferral Plan,
5.: Registration Statement (Form S-8 No. 333-195194) pertaining to the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan,
6.: Registration Statement (Form S-8 No. 333-145305) pertaining to the: 1) Amicus Therapeutics, Inc. 2002 Equity Incentive Plan, as Amended, 2) Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, 3) Amicus Therapeutics, Inc. 2007 Director Option Plan, 4) Amicus Therapeutics, Inc. 2007 Employee Stock Purchase Plan,
7.: Registration Statement (Form S-8 No. 333-157219) pertaining to the: 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. 2007 Director Option Plan,
8.: Registration Statement (Form S-8 No. 333-174900) pertaining to the: 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan,

of our reports dated March 1, 2017 with respect to the consolidated financial statements of Amicus Therapeutics, Inc., and the effectiveness of internal control over financial reporting of Amicus Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2016.

/s/ Ernst & Young LLP

Iselin, New Jersey
March 1, 2017

QuickLinks

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.